Skip to content
NASDAQ · RETAIL-DRUG STORES AND PROPRIETARY STORES · SMALL CAP

Ridgetech Inc. RDGT

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$132.2M
▲ 10.2% YoY
$-1.3M
▼ 112.3% YoY
$-1.4M
▼ 227.6% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Ridgetech, Inc. is a wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. It operates in the offline wholesale distribution of pharmaceutical products primarily to local buyers, while also engaging in online sales through both its self-operated and third-party platforms to customers nationwide. Its wholesale business is conducted primarily through subsidiaries of Renovation, including Zhejiang Jiuxin Medicine Co., Ltd., acquired in August 2011, and Allright (Hangzhou) Internet Technology Co. Ltd, acquired in February 2025. Allright operates in the B2B sector, providing wholesale distribution and online sales through self-operated and third-party platforms, with a focus on pharmaceuticals, medical devices, health foods, cosmetics and daily necessities. As of June 2026, it offered more than 5,000 varieties of products and served over 180,000 customers, including retail pharmacies, clinics and other vendors across the country. For the fiscal year ended March 31, 2026, the Company had one customer that accounted for more than 10 percent of its total sales from continuing operations, at 53.7 percent. As of March 31, 2026, it had 64 employees combined in its wholesale operation. The company was incorporated in Nevada on December 19, 2006, under the name "Kerrisdale Mining Corporation," with a principal business objective to acquire and develop mineral properties.

Written from the business description in Ridgetech, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 July 2026. Every sentence was checked against that document before publication.

Growth

USD 132.2M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 132.2 · Net income -1.3
100M200M-10M-20M
201920222025
Compound annual growth
+3.2%
−0.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −0.1% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−1 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -1.4% · Net -0.9%
5%-5%-10%-15%
201920222025
ROE
FY2025 · ROE -3.6%
20%40%-50%-100%
201920222025
Three returns, three denominators.

Each USD of equity lost 4 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -1.4
0.5M1.0M-3.0M-6.0M
201920222025

Total assetsUSD 69.0M
CashUSD 17.9M
Current ratio2.31×

Not available: we don't have the total debt figure for this period.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
RDGT, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B0.10.10.10.10.20.10.1
Operating income $B−0.0−0.00.0−0.0−0.0−0.0−0.0
EBITDA $B−0.00.00.0−0.0−0.0−0.0−0.0
Income tax $B−0.00.0−0.00.00.00.00.0
Net income $B−0.00.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.00.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−17.21275.87−439.78−41.46−18.35−2.39−2.16
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %−3.645.0−25.2−100.4−12.8−36.5−31.0
Shares out B0.000.000.000.020.000.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 33 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 12 checks were skipped: EPS is not tagged before 2019. 12 checks were skipped: revenue is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityRetail-Drug Stores and Proprietary Stores
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsMarch 31
Data on record since2019

Share this section

Download image